NR1H4 and renal fibrosis: FXR activation has been shown to interfere with renal overexpression of SREBP-1 and lipogenic enzymes, inhibit the nuclear factor kappaB (NF-κB) pathway, and protect against renal fibrosis by suppressing SMAD3 expression and regulating the FXR-Src-YAP pathway19–22.